Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018
According to the recently published report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018' outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 6, 1 and 4 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Musculoskeletal Disorders, Dermatology, Gastrointestinal and Respiratory which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Colorectal Cancer, Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Actinic (Solar) Keratosis, Allergic Rhinitis, Arthritis, Autoimmune Disorders, Breast Cancer, Crohn's Disease (Regional Enteritis), Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sarcomas, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ulcerative Colitis and Warts.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook